Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial

Lancet

Volumn 350, Issue 9072, 1997, Pages 161-165

  Saunders, Michele ^a   Dische, Stanley ^a   Barrett, Ann ^c   Harvey, Angela ^c   Gibson, Della ^c   Parmar, Mahesh ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DYSPHAGIA; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL;

EID: 0030737527     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06305-8     Document Type: Article

References (25)

1. Parkin DM. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Standing Medical Advisory Committee Report on Working Party (chaired by Whitehouse JMA). Management of lung cancer - current clinical practices. Bethesda: ICRU, 1994; 18.
3. Noordijk EM, Poest Clement EVD, Hermans J, Wever AMJ, Leer WJH. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988; 13: 83-89.
4. Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968; 90: 688-97.
5. Perez CA, Pajak TF, Rubin P, et al. Long-term observation of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Oncology Group. Cancer 1987; 59:1874-881.
6. Payne DG. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy? J Clin Oncol 1988; 6: 552-58.
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
8. Saunders MI, Bennett MH, Dische S, Anderson PJ. Primary tumor control after radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 1984; 10: 499-501.
9. Cox JD. Induction chemotherapy for non-small cell carcinoma of the lung: limitations and lessons. Int J Radiat Oncol Biol Phys 1991; 20: 1375-76.
10. Saunders MI. Is control of the primary tumour worthwhile in non-oat cell carcinoma of the bronchus? Clin Oncol 1991; 3: 185-88.
11. Wilson GD, McNally NJ, Dische S, et al. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1988; 58: 423-31.
12. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiat 1989; 62: 679-94.
13. Saunders MI, Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 1990; 19: 1211-15.
14. Saunders MI, Dische S, Barrett A, et al. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer 1996; 73: 1455-62.
15. International Commission on Radiation Units and Measurements, Report 29. Dose specification for reporting external beam therapy with photons and electrons; 1 April 1978. Department of Health.
16. Parmar MKB, Spiegelhalter DJ, Freedman LS. The CHART trials: Bayesian design and monitoring in practice. Stat Med 1994; 13: 1297-312.
17. Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester: John Wiley, 1995.
18. Green MR, Cox JD, Ardizzoni A, et al. Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. Lung Cancer 1994; 11 (Suppl 3): S11-13.
19. Aird EGA, Williams C, Mott GTM, Dische S, Saunders MI. Quality assurance in the CHART clinical trial. Radiother Oncol 1995; 36: 235-45.
20. Drummond MF, Coyle D, et al. Costs of conventional radical radiotherapy versus continuous, hyperfractionated, accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer and carcinoma of the bronchus. Clin Oncol (in press).
21. Jones A. Transient radiation myelopathy (with reference to Lhermittes sign of electrical paraesthesia). Br J Radiat 1964; 37: 727-44.
22. Dillman RO, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy vs. radiation therapy alone in stage III non small cell lung cancer: five-year follow up of CALGB 84-33. Proc Am Soc Clin Oncol 1993; 12: 329 (abstr).
23. Sause WT, Scott C, Taylor S et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
24. Morton RF, Jett JR, McGinnis I, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small-cell lung cancer. Ann Intern Med 1991; 115: 681-86.
25. Dische S, Saunders MI, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol (in press).